[Regression of hepatocellular carcinoma under Tamoxifen: report of one case and review of the literature].
Hepatocellular carcinoma is a malignant tumor with a poor prognosis, particularly when it is unresectable. The results of tamoxifen treatment in hepatocellular carcinoma have been disappointing and randomized studies have shown conflicting results. We report the case of a 72-yr-old-man with histologically confirmed hepatocellular carcinoma on a normal liver, that regressed with tamoxifen treatment. Regression was confirmed by normalization of serum alpha-fetoprotein levels and a significant decrease in radiological lesions by 66%. The patient was alive in excellent clinical condition more than 30 months after the initial diagnosis.
Macaigne
Gilles
G
Service d'Hépato-Gastroentérologie, Hôpital de Lagny-Marne-la-Vallée, 77405 Lagny-sur-Marne Cedex, France.
Auriault
Marie-Luce
ML
Boivin
Jean-François
JF
Cheaib
Sadek
S
Chayette
Claude
C
Deplus
Renaud
R
D000368:Aged; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000188:drug therapy*; D008297:Male; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome; D000509:alpha-Fetoproteins / Q000032:analysis
D016588:Anticarcinogenic Agents; D000509:alpha-Fetoproteins; D013629:Tamoxifen